Business Context and Reporting Period
This Form 8-K filing by Personalis, Inc. (PSNL) reports a corporate governance event dated March 13, 2026. The filing details the appointment of a new President and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation adjustments.
- Base Salary Increase: Richard Chen's annual base salary will increase to $570,000, effective April 1, 2026.
- Performance Bonus: Target increased to 70% of the annual base salary.
- Equity Grants:
- Stock Option: 37,500 shares (vesting monthly over 36 months).
- Restricted Stock Units (RSUs): 6,250 shares (vesting bi-annually over 3 years).
Material Changes
The primary material change is the leadership transition within the executive suite:
- Appointment: Richard Chen appointed as President, in addition to his existing roles as Executive Vice President, R&D, and Chief Medical Officer.
- Departure: Christopher Hall, the current CEO, previously served as President and is stepping down from that specific title while remaining CEO.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking financial guidance, risk factors, or management commentary regarding business strategy or market conditions. The document is strictly a disclosure of the appointment and the terms of the new compensation package under the 2019 Equity Incentive Plan.
Investor Verification Checklist
- Verify the impact of the $570,000 salary increase and equity grants on the company's near-term cash burn and stock-based compensation expenses.
- Confirm the vesting schedules for the 37,500 stock options and 6,250 RSUs to assess future dilution.
- Review the rationale for the leadership change to understand if it signals a strategic shift in R&D or clinical operations.
- Check the closing stock price on March 13, 2026, to determine the exercise price of the new stock options.